Abstract Background Circulating tumor DNA (ctDNA) is an emerging tool for non-invasive disease monitoring in solid tumor oncology, yet its clinical utility in renal cell carcinoma (RCC) remains poorly defined. RCC exhibits variable ctDNA shedding rates, which may limit assay sensitivity particularly in low-burden disea...
Ezra Blumenthal, Paulo Siqueira Do Amaral, Yi Chen et al.· The Oncologist· 0 citations
This analysis compares somatic, germline, immune, transcriptomic, and clinical features of eoRCC vs. typical-onset RCC (toRCC) using a multi-omic real-world dataset and reveals upregulation of hypoxia- and VEGFR-signaling pathways in early-onset ccRCC.
H. Ebrahimi, S. Haake, M. Weitz et al.· The Oncologist· 0 citations
Abstract Background Papillary renal cell carcinoma (pRCC) is the second most common histology of kidney cancer diagnosed in adults. However, the biologic drivers of recurrence after nephrectomy remain poorly defined, and no molecular biomarkers are routinely used in clinical practice to estimate prognosis. The primary...
W. J. Brewer, Joseph A. Vento, Ezra Blumenthal et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.